報價延遲最少15分鐘:2025/03/28 08:24 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.19 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.02/-1.16
|
|
企業價值
825.59M
|
| 資產負債 |
|
每股賬面淨值
4.96
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
131.16M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/03/28 08:24 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor. |